Skip to main content
Premium Trial:

Request an Annual Quote

Structural Genomix Raises $45M in Private Placement

NEW YORK, Sept 20 – Structural Genomix of San Diego, Calif., said Wednesday it raised $45 million in a private equity financing, bringing the amount of money the company has raised this year to $77 million.

BA Venture Partners led the round while Amerindo, MDS Health Ventures, Orbimed Advisors, and Vector Fund Management also invested in Structural Genomix, a company involved in determining protein structures.

Previous investors, including Atlas Ventures, Apple Tree Partners, Prospect Venture Partners, The Sprout Group, Index Ventures, and Vulcan Northwest, also participated in the latest round of financing.

Structural Genomix said in a statement it would use the financing to build its technology platform, which uses X-ray crystallography to transform DNA sequences into three-dimensional protein structures. The company hopes to sell its information regarding protein structures to pharmaceutical and biotechnology companies involved in developing drugs and vaccines.

In July, the company signed a memorandum of understanding with the U.S. Department of Energy’s Advanced Photon Source to build a dual undulator beamline facility, which would provide the company with access to intense X-rays beams from the DOE’s synchrotron radiation source.


The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.